How do physical capacity, fatigue and performance differ in children with duchenne muscular dystrophy compared with their healthy peers?

Akmer Mutlu, Halil Alkan, Tuzun Fırat, Aynur A Karaduman, Oznur T Yilmaz, Akmer Mutlu, Halil Alkan, Tuzun Fırat, Aynur A Karaduman, Oznur T Yilmaz

Abstract

Objective: To compare the fatigue levels and energy expenditure of children with Duchenne Muscular Dystrophy (DMD) at different functional levels with healthy children.

Methods: The cross-sectional study was carried out in the Unit of Pediatric Neuromuscular Diseases in the Department of Physiotherapy and Rehabilitation, Faculty of Health Science, Hacettepe University between March 2015 and January 2016. Fifty two children diagnosed with DMD in Level I-III according to the Brooke Functional Classification Scale and 17 healthy children were included in the study. The Six Minute Walk Test (6MWT), Northstar Ambulatory Assessment Scale (NSAA), Physiological Cost Index (PCI), and Timed performance tests were used to assess the children.

Results: Comparison in terms of PCI indicated a difference between Levels 2 and 3, and Levels 1 and 3 (p<0.0083). A difference was found in ascending and descending 4 stairs after 6MWT when fatigue after activity was evaluated.

Conclusion: The walking distances, fatigue levels and energy expenditure of DMD patients were higher than the healthy peers. This difference was more prominent with decreasing functional level.

References

    1. Kohler M, Clarenbach CF, Bahler C, Brack T, Russi EW, Bloch KE. Disability and survival in Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry. 2009;80:320–325.
    1. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9:77–93.
    1. Goemans N, Van den Hauwe M, Wilson R, Van Impe A, Klingels K, Buyse G. Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids. Neuromuscul Disord. 2013;23:618–623.
    1. Karaduman A, Yılmaz Ö, Alemdaroğlu İ. Pediatric Physical Therapy and Rehabilitation in Neuromuscular Disorders. Ankara (Turkey): Pelikan press; 2014.
    1. McDonald CM, Abresch RT, Carter GT, Fowler Jr WM, Johnson ER, Kilmer D, et al. Profiles of neuromuscular diseases: Duchenne muscular dystrophy. Am J Phys Med Rehabil. 1995;74:93.
    1. Tunçbay T, Tunçbay E. Muscular Dystrophies: Neuromuscular Disorders. İzmir (Turkey): Nobel Medical Publications; 2004. pp. 418–497.
    1. Mathieu J, Boivin H, Meunier D, Mathieu J, Boivin H, Meunier D, et al. Assessment of a disease-spesific muscular impairment rating scale in myotonic dystrophy. Neurology. 2001;56:336–340.
    1. Edwards RH. Human muscle function and fatigue. In Human muscle fatigue: physiological mechanisms. Pitman Medical London. 1981;82:1–18.
    1. Maclaren DP, Gibson H, Parry-Billings MARK, Edwards RH. A review of metabolic and physiological factors in fatigue. Exerc Sport Sci Rev. 1989;17:29–66.
    1. Kalkman JS, Schillings ML, Van der Werf S, Padberg GW, Zwarts MJ, van Engelen BGM, et al. Experienced fatigue in facioscapulohumeral dystrophy, myotonic dystrophy, and HMSN-I. J Neurol Neurosurg Psychiatry. 2005;76:1406–1409.
    1. Miller RG. Role of fatigue in limiting physical activities in humans with neuromuscular diseases. Am J Phys Med Rehabil. 2002;81:99–107.
    1. Kalkman JS, Schillings ML, Zwart MJ, van Engelen BG, Bleijenberg G. The development of a model of fatigue in neuromuscular disorders: a longitudinal study. J Psychosom Res. 2007;62:571–579.
    1. Vignos PJ, Spencer GE, Archibald KC. Management of progressive muscular dystrophy of childhood. Jama. 1963;184:89–96.
    1. Brooke MH, Griggs RC, Mendell JR, Fenichel GM, Shumate JB, Pellegrino RJ. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle nerve. 1981;4:186–197.
    1. McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, Elfring GL, et al. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve. 2010;41:500–510.
    1. Feasson L, Camdessanché JP, El Mhandi L, Calmels P, Millet GY. Fatigue and neuromuscular diseases. Ann Readapt Med Phys. 2006;49:375–384.
    1. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111.
    1. Mcdonald CM, Henricson EK, Abresch RT, Florence JM, Eagle M, Gappmaier E, et al. The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: Longitudinal natural history observations over 48 weeks from a multicenter study. Muscle nerve. 2013;48:343–356.
    1. Mazzone ES, Messina S, Vasco G, Main M, Eagle M, D'Amico A, et al. Reliability of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscul Disord. 2009;19:458–461.
    1. Ijzerman MJ, Nene AV. Feasibility of the physiological cost index as an outcome measure for the assessment of energy expenditure during walking. Arch Phys Med Rehabil. 2002;83:1777–1782.
    1. Keefer DJ, Tseh W, Caputo JL, Apperson K, McGreal S, Morgan D. Comparison of direct and indirect measures of walking energy expenditure in children with hemiplegic cerebral palsy. Dev Med Child Neurol. 2004;46:320–324.
    1. Boyd R, Fatone S, Rodda J, Olesch C, Starr R, Cullis E, et al. High- or low- technology measurements of energy expenditure in clinical gait analysis. Dev Med Child Neurol. 1999;41:676–682.
    1. Aboussouan LS. Mechanisms of exercise limitation and pulmonary rehabilitation for patients with neuromuscular disease. Chron Respir Dis. 2009;6:231–249.
    1. Bèlanger AY, Noël G, CÔte C. A comparison of contractile properties in the preferred and nonpreferred leg in a mixed sample of dystrophic patients. Am J Phys Med Rehabil. 1991;70:201–205.
    1. Schillings ML, Kalkman JS, Janssen HM, Van Engelen BGM, Bleijenberg G, Zwarts MJ. Experienced and physiological fatigue in neuromuscular disorders. Clin Neurophysiol. 2007;118:292–300.
    1. Montes J, Blumenschine M, Dunaway S, Alter AS, Engelstad K, Rao AK, et al. Weakness and fatigue in diverse neuromuscular diseases. J Child Neurol. 2013;28:1277–1283.
    1. Lachmann R, Schoser B. The clinical relevance of outcomes used in late-onset Pompe disease: can we do better. Orphanet J Rare Dis. 2013;8:160.
    1. Mazzone E, Martinelli D, Berardinelli A, Messina S, D'Amico A, Vasco G, et al. North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2010;20:712–716.
    1. Martini J, Hukuda ME, Caromano FA, Favero FM, Fu C, Voos MC. The clinical relevance of timed motor performance in children with Duchenne muscular dystrophy. Physiother Theory Pract. 2015;31:173–181.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅